spacer
home > > summer 2019 > overcoming the industry data crisis
PUBLICATIONS


Overcoming the Industry Data Crisis




The amount of data generated around the world is growing exponentially and at rates that are so great they are difficult to grasp. By one calculation, 90% of the world’s data have been generated over the last two years (1). To put it in terms used by the International Data Corporation in its estimates: by 2025, the global datasphere will reach 175 zettabytes − the equivalent of 175 trillion gigabytes (2).

With data from the newest technologies, applications, devices, and wearables all contributing, the sheer breadth of available information in clinical research is staggering, and its potential for contributing positively to modernisation is virtually limitless. The pharmaceutical industry has progressively accepted electronic data capture (EDC) as the standard practice for clinical trials. Overall, the adoption of EDC has resulted in some improvement across the industry − relative to antiquated paper processes − but EDC still largely relies on paper-based source documents (3).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author

 
Ed Seguine, CEO at Clinical Ink, is passionate about creating solutions for problems caused by current clinical trial processes and technologies. With more than 20 years of experience as a clinical technology executive at Big Pharma and startup organisations, Ed, a thought leader on key initiatives including CDISC and eClinical Forum, often presents at industry events and publishes regularly on the benefits of next-generation eSource solutions. He earned a Master of Business Administration from Indiana University, Bloomington, US, and a Bachelor of Science in Finance from Brigham Young University, US.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Over 300 Clinical Studies Benefit from CluePoints COVID-19 Risk Management Support

CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, today announced the success of its complimentary COVID-19 risk management package alongside comprehensive support for COVID-19 affected trials.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement